Lexicon Pharmaceuticals (LXRX) Non-Current Debt (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 16 years of Non-Current Debt data on file, last reported at $49.7 million in Q1 2026.

• On a quarterly basis, Non-Current Debt fell 15.28% year-over-year to $49.7 million in Q1 2026; TTM through Mar 2026 was $49.7 million, a 15.28% decrease from a year earlier, with the FY2025 full-year figure at $49.4 million, down 50.74% from the prior year.
• Non-Current Debt for Q1 2026 stood at $49.7 million, up from $49.4 million in the prior quarter.
• Over the last five years, Non-Current Debt for LXRX reached as high as $100.3 million in Q4 2024 and fell as low as $23.5 million in Q1 2022.
• Historically, Non-Current Debt has averaged $66.8 million across 5 years, with a median of $56.5 million in 2025.
• Across the five-year window, Non-Current Debt jumped 318.64% in 2023 and plunged 50.74% in 2025, its largest moves.
• Year by year, Non-Current Debt stood at $48.6 million in 2022, then jumped by 104.84% to $99.5 million in 2023, then advanced by 0.79% to $100.3 million in 2024, then slumped by 50.74% to $49.4 million in 2025, then advanced by 0.56% to $49.7 million in 2026.
• Per Business Quant data, the three most recent Non-Current Debt figures were $49.7 million in Q1 2026, $49.4 million in Q4 2025, and $56.5 million in Q3 2025.